5月16日 - ** 罕见病疗法开发商Inozyme Pharma INZY.O的股价盘前上涨179%至3.96美元
** BioMarin Pharma BMRN.O称， (link)，该公司已达成协议，将以每股4美元的价格收购Inozyme Pharma公司，全现金交易总价约为2.7亿美元。
** 预计交易将于2025年第三季度完成
** BMRN称，该交易将加强BioMarin的酶疗法产品组合，增加一种晚期酶替代疗法INZ-701，该疗法目前正在接受评估，以治疗一种影响血管、软组织和骨骼的罕见遗传性疾病。
** 截至上次收盘，INZY年累计下跌48.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.